ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.95
0.34 (3.95%)
▲
5d:
+2.64%
30d:
+17.76%
90d:
-1.76%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.5/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 10.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 10.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.27
Based on 13.3% avg growth
INTRINSIC VALUE TODAY
$14.45
38.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.95, which is considered extended relative to its 30-day fair value range of $7.95 to $8.63. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.0) compared to its historical average (12.6). Remarkably, the market is currently pricing in an annual earnings decline of 10.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $9.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+96.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $9.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+96.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.95 -
$8.63
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 96.6% below Wall St target ($17.60)
Trading Range Analysis
30-Day Trading Range
$7.95 -
$8.63
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.23
Resistance Level
$9.04
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.97
Wall Street Target
$17.60
(+96.6%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-10.8% cheaper
PE vs Historical
9.0 vs 12.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.8%
(market-implied from PE analysis)
1-Year Target
$8.05
(-10%)
2-Year Target
$7.25
(-19%)
3-Year Target
$6.52
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→13)
$9.16
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.6%)
$40.08
(+348%)
Base:
(SPY PE: 9.0, Growth: 22.6%)
$16.51
(+85%)
Bear:
(PE: 7.6, Growth: 22.6%)
$14.04
(+57%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.66 | Current EPS (TTM): $0.68
Bull Case
$13.89
(+55%)
Analyst growth 46.7%, PE expands to 13.9
Base Case
$12.63
(+41%)
Market implied 46.7%, PE stable at 12.7
Bear Case
$5.85
(-35%)
Severe decline -20.0%, PE contracts to 10.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.0 to 12.6
Stabilization Target:
$12.57
(+40.4%)
PE Expansion Potential:
+40.4%
Share & Embed Analysis
Last updated: July 03, 2026 8:08 PM ET
Data refreshes hourly during market hours. Next update: 9:08 PM
Data refreshes hourly during market hours. Next update: 9:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$89 | 64 BUY |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
